Zobrazeno 1 - 10
of 352
pro vyhledávání: '"Violeta, Serra"'
Autor:
Andrea Herencia-Ropero, Alba Llop-Guevara, Anna D. Staniszewska, Joanna Domènech-Vivó, Eduardo García-Galea, Alejandro Moles-Fernández, Flaminia Pedretti, Heura Domènech, Olga Rodríguez, Marta Guzmán, Enrique J. Arenas, Helena Verdaguer, Fernando J. Calero-Nieto, Sara Talbot, Luis Tobalina, Elisabetta Leo, Alan Lau, Paolo Nuciforo, Rodrigo Dienstmann, Teresa Macarulla, Joaquín Arribas, Orland Díez, Sara Gutiérrez-Enríquez, Josep V. Forment, Mark J. O’Connor, Mark Albertella, Judith Balmaña, Violeta Serra
Publikováno v:
Genome Medicine, Vol 16, Iss 1, Pp 1-17 (2024)
Abstract Background Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors (PARPi) are targeted therapies approved for homologous recombination repair (HRR)-deficient breast, ovarian, pancreatic, and prostate cancers. Since inhibition of PARP1 is
Externí odkaz:
https://doaj.org/article/68b3f150f248467b98d10c77d2ec9d7a
Autor:
Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Olga Martínez-Sáez, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco Pardo, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, Maria Vidal, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Patritumab deruxtecan (HER3-DXd) exhibits promising efficacy in breast cancer, with its activity not directly correlated to baseline ERBB3/HER3 levels. This research investigates the genetic factors affecting HER3-DXd’s response in women w
Externí odkaz:
https://doaj.org/article/7c7d4486147e4021ad5651e0e2b54a88
Autor:
Laura Pascual‐Reguant, Queralt Serra‐Camprubí, Debayan Datta, Damiano Cianferoni, Savvas Kourtis, Antoni Gañez‐Zapater, Chiara Cannatá, Lorena Espinar, Jessica Querol, Laura García‐López, Sara Musa‐Afaneh, Maria Guirola, Anestis Gkanogiannis, Andrea Miró Canturri, Marta Guzman, Olga Rodríguez, Andrea Herencia‐Ropero, Joaquin Arribas, Violeta Serra, Luis Serrano, Tian V Tian, Sandra Peiró, Sara Sdelci
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 12, Pp 1-23 (2023)
Abstract Triple‐negative breast cancer (TNBC) often develops resistance to single‐agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergis
Externí odkaz:
https://doaj.org/article/a9ac7e4ea8d342f3a90f379ec5eb682e
Autor:
Claire JH Kramer, Alba Llop‐Guevara, Elisa Yaniz‐Galende, Benedetta Pellegrino, Natalja T terHaar, Andrea Herencia‐Ropero, Nicoletta Campanini, Antonino Musolino, Tjalling Bosse, Alexandra Leary, Violeta Serra, Maaike PG Vreeswijk
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 9, Iss 6, Pp 442-448 (2023)
Abstract The RAD51 test is emerging as a promising biomarker for the assessment of functional homologous recombination deficiency (HRD). Yet, the robustness and reproducibility of the immunofluorescence‐based RAD51 test, in different academic labor
Externí odkaz:
https://doaj.org/article/fba349eabeb84ca8af5db56235c061a6
Autor:
María Jimena Rodriguez, María Cecilia Perrone, Marina Riggio, Marta Palafox, Valeria Salinas, Andrés Elia, Natali Daiana Salgueiro, Andrea Eugenia Werbach, María Paula Marks, Marcelo A. Kauffman, Luciano Vellón, Violeta Serra, Virginia Novaro
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)
Abstract Resistance to therapy remains a major obstacle in cancer management. Although treatment with hormone and CDK4/6 inhibitors is successful in luminal breast cancer, resistance to these treatments is frequent, highlighting the need for novel th
Externí odkaz:
https://doaj.org/article/894327144ae548bf939fc2408e72085d
Autor:
Jennifer B. Shah, Dana Pueschl, Bradley Wubbenhorst, Mengyao Fan, John Pluta, Kurt D’Andrea, Anna P. Hubert, Jake S. Shilan, Wenting Zhou, Adam A. Kraya, Alba Llop Guevara, Catherine Ruan, Violeta Serra, Judith Balmaña, Michael Feldman, Pat J. Morin, Anupma Nayak, Kara N. Maxwell, Susan M. Domchek, Katherine L. Nathanson
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-19 (2022)
Carriers of pathogenic BRCA1/2 variants have a higher risk of breast and ovarian cancers, which recur frequently. Here, the authors sequence primary and recurrent tumours of BRCA1/2 mutation carriers, finding PARP1 amplifications, differential BRCA2
Externí odkaz:
https://doaj.org/article/86e2b8acb27543e9aad8ac4d1b5b8463
Autor:
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S. Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-20 (2022)
CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects.
Externí odkaz:
https://doaj.org/article/c3a330e420d34dc992aab0ec2b80986a
Autor:
Florian J Groelly, Manuela Porru, Jutta Zimmer, Hugo Benainous, Yanti De Visser, Anastasiya A Kosova, Serena Di Vito, Violeta Serra, Anderson Ryan, Carlo Leonetti, Alejandra Bruna, Annamaria Biroccio, Madalena Tarsounas
Publikováno v:
EMBO Molecular Medicine, Vol 14, Iss 3, Pp 1-22 (2022)
Abstract The cells with compromised BRCA1 or BRCA2 (BRCA1/2) function accumulate stalled replication forks, which leads to replication‐associated DNA damage and genomic instability, a signature of BRCA1/2‐mutated tumours. Targeted therapies again
Externí odkaz:
https://doaj.org/article/02c619b0acf544c3b51f32c37322ca42
Autor:
Roberto Dinami, Luca Pompili, Eleonora Petti, Manuela Porru, Carmen D'Angelo, Serena Di Vito, Angela Rizzo, Virginia Campani, Giuseppe De Rosa, Alejandra Bruna, Violeta Serra, Miguel Mano, Mauro Giacca, Carlo Leonetti, Gennaro Ciliberto, Madalena Tarsounas, Antonella Stoppacciaro, Stefan Schoeftner, Annamaria Biroccio
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 1, Pp n/a-n/a (2023)
Abstract The telomeric repeat‐binding factor 2 (TRF2) is a telomere‐capping protein that plays a key role in the maintenance of telomere structure and function. It is highly expressed in different cancer types, and it contributes to cancer progre
Externí odkaz:
https://doaj.org/article/329d8d14529b400796d6b5c09e60a4e4
Autor:
Laia Castells-Roca, Sara Gutiérrez-Enríquez, Sandra Bonache, Massimo Bogliolo, Estela Carrasco, Miriam Aza-Carmona, Gemma Montalban, Núria Muñoz-Subirana, Roser Pujol, Cristina Cruz, Alba Llop-Guevara, María J. Ramírez, Cristina Saura, Adriana Lasa, Violeta Serra, Orland Diez, Judith Balmaña, Jordi Surrallés
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly her
Externí odkaz:
https://doaj.org/article/f5fbf0683dd64720a1c4fee28554ad68